Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 22;14:4901–4913. doi: 10.2147/JIR.S329401

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Lawal et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

In vitro anti-breast cancer activity of HH-N25. (A) Antiproliferative activities of HH-N25 against NCI60 human cancer cell lines. The percentage growth inhibition of each cell line relative to the mean is represented by values under 100, whereas those values below 0 indicate cell death. (B) Line graph showing the effect of HH-N25 on the viability of breast cancer cell lines. (C) 50% inhibitory concentration (IC₅₀) values of HH-N25 against a panel of breast cancer cell lines. (D) NCI standard anticancer agent shared similar anticancer fingerprints and mechanistic correlations with HH-N25.

Abbreviations: CCLC, common cell line count; Cor, Pearson’s correlation coefficient.